Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
About Ipsen
Ipsen is a global specialty-driven
biopharmaceutical group focused on innovation and specialty care. The
group develops and commercializes innovative medicines in three key
therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its
commitment to oncology is exemplified through its growing portfolio of
key therapies for prostate cancer, neuroendocrine tumors, renal cell
carcinoma and pancreatic cancer. Ipsen also has a well-established
Consumer Healthcare business. With total sales close to €1.6 billion in
2016, Ipsen sells more than 20 drugs in over 115 countries, with a
direct commercial presence in more than 30 countries. Ipsen's R&D is
focused on its innovative and differentiated technological platforms,
and centers located in the heart of leading biotechnological and life
sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The
Group has about 5,100 employees worldwide. Ipsen is listed in Paris
(Euronext: IPN) and in the United States through a Sponsored Level I
American Depositary Receipt program (ADR: IPSEY). For more information
on Ipsen, visit www.ipsen.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180102005336/en/
Contacts:
Ipsen
Media
Ian
Weatherhead, +44 (0) 7584230549
Vice-President, Corporate
External communications
ian.weatherhead@ipsen.com
or
Brigitte
Le Guennec, +33 (0)1 58 33 51 17
Senior Manager, Global
External Communications
brigitte.le.guennec@ipsen.com
or
Financial
Community
Eugenia Litz, +44 (0) 1753 627721
Vice-President
Investor Relations
eugenia.litz@ipsen.com
or
Côme
de La Tour du Pin, +33 (0)1 58 33 53 31
Investor Relations
Manager
come.de.la.tour.du.pin@ipsen.com